ANDA 208177, held by Mylan. Atazanavir Sulfate.
As of Nov 15, 2026, ANDA 208177 (Atazanavir Sulfate), held by Mylan, was first approved by FDA on Sep 24, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 2018 | Original application | Approved | None posted |
| Atazanavir SulfateEQ 150MG BASE · capsule;oral | Atazanavir Sulfate | Discontinued |
| Atazanavir SulfateEQ 200MG BASE · capsule;oral | Atazanavir Sulfate | Discontinued |
| Atazanavir SulfateEQ 300MG BASE · capsule;oral | Atazanavir Sulfate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
